Abstract Library

#4599 Endosonography guided coloenterostomy for management of malignant small bowel ileus

Introduction: Small-bowel ileus (SBI) is often decisive for the prognosis in midgut neuroendocrine tumours (NET) and other peritoneally metastasised neoplasias. Conventional procedures of palliative care deliver unsatisfying results.

Conference:

Presenting Author: Weich A

Authors: Weich A, Retzbach L, Hartung V, Brand M, Kudlich T,

Keywords: Coloenterostomy, Endosonography, small bowel ileus, peritoneal carcinomatosis, midgut NET,

#4553 The efficacy of “rechallenge” peptide receptor radionuclide therapy (PRRT) may be inferior to that of the initial PRRT, while the safety profile remains comparable

Introduction: Data on efficacy and adverse events of re-challenge PRRT (re-PRRT) for patients with gastrointestinal neuroendocrine tumours (GI-NETs) are limited.

Conference:

Presenting Author: Heinrich M

Authors: Heinrich M, Lutz F, Alwers S, Däubler C, Buck A,

Keywords: gastrointestinal neuroendocrine tumour, somatostatin receptor directed PET, laboratory parameters, Progression-free survival,

#4535 Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%

Introduction: In patients (pts) with an advanced well-differentiated (WD-NET) with a Ki-67>10% and ≤20% (“G2 high”), chemotherapy (ChT) or targeted therapies are the preferred first-line palliative options. Somatostatin analogues (SSAs) may offer an alternative, yet randomised evidence is lacking.

Conference:

Presenting Author:

Authors: Dawoodji A, Nuttall C, Eyong M, Farrell K, Barratt N,

Keywords: somatostatin analogue, SSA, non-SSA, Grade 2 well-differentiated neuroendocrine tumour, WD-NET,

#4389 The LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumours (NETs) – Interim results of step 1

Introduction: LOLA is an Italian, multicentre, open-label, double cohort, non-randomised, 3-stage, phase 2 trial aiming to assess the safety and activity of the combination of cabozantinib (CABO) + lanreotide (LAN) in patients (pts) with advanced or metastatic GEP and unknown primary NETs with Ki-67 > 10% or thoracic NET. In NETs sunitinib is the only TKI approved in advanced pancreatic NETs. While CABO has been reported superior to sunitinib in renal cancer its role in NETs is still investigational.

Conference:

Presenting Author: Oldani S

Authors: Oldani S, Morano F, Brizzi M, Giuffrida D, Panzuto F,

Keywords: gastroenteropancreatic neuroendocrine tumour, cabozantinib, lanreotide, clinical trial,

#4242 Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,